Posted by Michael Wonder on 20 Mar 2022
NHS fast tracks new ‘gamechanging’ drug for lung cancer
18 March 2022 - A targeted new drug for a rare and aggressive form of lung cancer will be fast-tracked to eligible patients within weeks, thanks to a deal brokered by NHS England.
Patients in England will be the first in Europe to access mobocertinib – the only precision drug available to patients with a mutation-driven, advanced form of lung cancer, who have already received chemotherapy.
